Mechanisms of metformin in humans.

Slides:

Advertisements

Similar presentations

Pharmacotherapy Oral Hypoglycemic Agents (OHA) Antihyperglycemic agents Used only in type 2 diabetes, with diet and exercise CDA Clinical Practice Guidelines.

Advertisements

 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.

SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA)

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

James Thrasher, MD The American Journal of Medicine

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

James Thrasher, MD The American Journal of Medicine

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

The risk of DR progression as related to mean HbA1c during DCCT

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Postprandial glucose flux in nondiabetic controls.

Metformin—Acting through Cyclic AMP as well as AMP?

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Completed and ongoing CVOTs (6–14,39,44–58)

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

Schematic representation of an MR analysis.

Glucose, insulin, and AGE levels during an OGC before and after RT

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

The underlying physiological basis of the HOMA model.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Representative study BG profiles from the forearm and.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG,

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

SDF-1, adiponectin, and sVCAM levels are higher in Medalists than controls, but SDF-1 does not differ with respect to vascular complications; PAI-1 and.

Comorbid conditions and concomitant medications.

Study design (A) and patient disposition (B).

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Distribution of daily frequency of BGM

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Schematic representation of the control of muscle glucose uptake during exercise. Schematic representation of the control of muscle glucose uptake during.

Pathophysiology and drug targets.

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

ROC curves showing the performance of the Diabetes Risk Score in predicting diabetes in the 1987 and 1992 cohorts; follow-up of both cohorts continued.

Antihyperglycemic therapy in adults with type 2 diabetes

Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.

Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Glucose-lowering medication in type 2 diabetes: overall approach.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Schematic diagram of the concept of hypoglycemia-associated autonomic failure and the pathogenesis of the syndromes of defective glucose counterregulation.

Presentation transcript:

Mechanisms of metformin in humans. Mechanisms of metformin in humans. A: Chemical structures of guanidine and metformin (dimethylbiguanide). Schematic diagrams showing the pharmacokinetics of Met XR (B) and Met DR (C) in oral administration and the underlying mechanisms for their respective antihyperglycemic effects. Bio-Avail., bioavailability; HGP, hepatic glucose output; LG Accum., lower gut accumulation; Met GLP, metformin glucose-lowering potency; ?, unknown. Ruisheng Song Dia Care 2016;39:187-189 ©2016 by American Diabetes Association